Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 166Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma 23Neoplasms, Plasma Cell 21Leukemia 21Recurrence 20Burkitt Lymphoma 18Lymphoma, Non-Hodgkin 15Neoplasms 14Lymphoma, Mantle-Cell 14Immunoglobulin Light-chain Amyloidosis 14Nausea 13Lymphoma, Large B-Cell, Diffuse 13Vomiting 12Breast Neoplasms 12Hodgkin Disease 11Waldenstrom Macroglobulinemia 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Amyloidosis 9Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Acute 8Smoldering Multiple Myeloma 7Neoplasm Metastasis 7Leukemia, Biphenotypic, Acute 6Hematologic Neoplasms 6Blast Crisis 6Prostatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, B-Cell 5

Interventions

Lenalidomide 2Dexamethasone 2ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × POEMS Syndrome × Calcium Dobesilate × Clear all
NCT02921893 2025-02-12

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Mayo Clinic

Phase EARLY_PHASE1 Completed
21 enrolled
Plasma cell

Plasmacytoma, POEMS Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡